256 related articles for article (PubMed ID: 26944860)
1. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Wu L; Shi W; Li X; Chang C; Xu F; He Q; Wu D; Su J; Zhou L; Song L; Xiao C; Zhang Z
J Transl Med; 2016 Mar; 14():66. PubMed ID: 26944860
[TBL] [Abstract][Full Text] [Related]
2. The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome.
Wu P; Geng S; Weng J; Deng C; Lu Z; Luo C; Du X
Leuk Res; 2015 Feb; 39(2):216-20. PubMed ID: 25533931
[TBL] [Abstract][Full Text] [Related]
3. [Functional study of hENT1 on SKM-1 cell resistance to decitabine].
Shi W; Wu L; Guo J; Xu F; Chang C; Li X
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):408-12. PubMed ID: 26031529
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Qin T; Castoro R; El Ahdab S; Jelinek J; Wang X; Si J; Shu J; He R; Zhang N; Chung W; Kantarjian HM; Issa JP
PLoS One; 2011; 6(8):e23372. PubMed ID: 21858090
[TBL] [Abstract][Full Text] [Related]
5. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
6. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M
Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180
[TBL] [Abstract][Full Text] [Related]
7. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
Damaraju VL; Mowles D; Yao S; Ng A; Young JD; Cass CE; Tong Z
Nucleosides Nucleotides Nucleic Acids; 2012; 31(3):236-55. PubMed ID: 22356238
[TBL] [Abstract][Full Text] [Related]
8. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome].
Bao ZH; Zhao HG; Yu HE
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1702-1707. PubMed ID: 30501707
[TBL] [Abstract][Full Text] [Related]
11. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
[TBL] [Abstract][Full Text] [Related]
13. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Wu L; Li X; Xu F; Chang C; He Q; Zhang Z; Zhang Y
Ann Hematol; 2012 Oct; 91(10):1547-54. PubMed ID: 22580751
[TBL] [Abstract][Full Text] [Related]
14. [p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].
Zhang Y; Song LX; Wu LY; Chang CK; Li X
Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):237-41. PubMed ID: 23683424
[TBL] [Abstract][Full Text] [Related]
15. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.
Ma D; Fang Q; Wang P; Gao R; Sun J; Li Y; Hu XY; Wang JS
Gene Ther; 2015 Apr; 22(4):287-96. PubMed ID: 25652099
[TBL] [Abstract][Full Text] [Related]
17. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
[TBL] [Abstract][Full Text] [Related]
18. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
[TBL] [Abstract][Full Text] [Related]
19. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
